Lipid peroxidation: pathophysiological and pharmacological implications in the eye

Area of Science:

• Ocular biochemistry
• Neuroscience
• Toxicology

Background:

• Reactive oxygen species (ROS) and subsequent lipid peroxidation are implicated in degenerative ocular diseases like AMD, cataracts, glaucoma, and diabetic retinopathy.
• Ocular tissues are vulnerable to ROS damage due to environmental factors, and peroxidation of long-chain polyunsaturated fatty acids (LCPUFAs) generates bioactive metabolites.
• Endogenous antioxidant defense mechanisms in the eye are crucial for preventing oxidative damage and offer potential therapeutic avenues.

Purpose of the Study:

• To investigate the role of oxygen-derived free radicals, lipid peroxidation, and their metabolites in ocular tissues.
• To explore the pharmacological and toxicological effects of peroxides and LCPUFA metabolites on neurotransmitter systems within the eye.
• To identify potential therapeutic targets for degenerative ocular diseases based on these mechanisms.

Main Methods:

• Literature review of studies on lipid peroxidation, ROS, and their effects in ocular tissues.
• Analysis of in vitro and in vivo data concerning the actions of hydrogen peroxide (H2O2), synthetic peroxides, isoprostanes, and neuroprostanes.
• Examination of effects on neurotransmitter release (glutamate, norepinephrine, dopamine) and concentrations in various ocular segments.

Main Results:

• Lipid peroxidation, driven by ROS, is a key factor in ocular tissue degeneration.
• H2O2 and synthetic peroxides impact neurotransmitter release and concentration in the anterior and posterior eye segments.
• Isoprostanes and neuroprostanes exhibit complex regulatory effects on neurotransmitter release, potentially modulating excitatory and inhibitory pathways without causing cell death.

Conclusions:

• Peroxides and LCPUFA metabolites significantly alter neurotransmitter pools in ocular tissues.
• These alterations highlight novel pathways and targets for the prevention and treatment of degenerative ocular diseases.
• Targeting these mechanisms may offer a new strategy for managing conditions like age-related macular degeneration and diabetic retinopathy.